

IN THE SPECIFICATION:

Please further amend the first paragraph on page 4, line 10 to page 6, line 11, as follows:

(Currently amended): In another aspect of the invention there is provided an inhibitor of ras farnesylation of Formula I wherein:


R¹ is selected from H; -C₁₋₄alkyl; -C₁₋₃alkylene-Ph optionally mono or di-substituted on Ph with substituents selected from C₁₋₄alkyl, halogen, OH, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkanoylamino, nitro, cyano, carboxy, carbamoyl, C₁₋₄alkoxycarbonyl, thiol, C₁₋₄alkylsulfanyl, C₁₋₄alkylsulfinyl, C₁₋₄alkylsulfonyl and sulfonamido; -CO-C₁₋₄alkyl; -CO-O-C₁₋₄alkyl; -CO-O-C₂₋₄alkenyl; -CO-O-(CH₂)_nPh optionally substituted on Ph as defined for substitution on Ph in R¹ = -C₁₋₃alkylene-Ph above and n=0-4; -C₁₋₄alkylene-CONR⁴R⁵ where R⁴ & R⁵ are independently selected from H and C₁₋₄alkyl; and -C₁₋₄alkylene-COOR⁶ where R⁶ is selected from H, C₁₋₄alkyl;

R² is selected from H; -C₁₋₄alkyl; -C₁₋₃alkylene-Ph optionally substituted on Ph as defined for substitution on Ph in R¹ = -C₁₋₃alkylene-Ph above; -COC₁₋₄alkyl; and -COOC₁₋₄alkyl;

R³ is selected from H; OH; CN; CF₃; NO₂; -C₁₋₄alkyl; -C₁₋₄alkylene-R⁷ where R⁷ is selected from phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R⁷ is optionally substituted as defined for substitution on the Ph group in R¹ = -C₁₋₃alkylene-Ph above; R⁷; C₂₋₄alkenyl; halogen; -(CH₂)_yCOOR⁸ where y= 0-3 and R⁸ represents H, C₁₋₄alkyl, or C₂₋₄alkenyl; -CONR⁹R¹⁰ where R⁹ and R¹⁰ independently represent H, C₁₋₄alkyl, C₂₋₄alkenyl, -O-C₁₋₄alkyl, -O-C₂₋₄alkenyl, -C₁₋₃alkylenePh optionally substituted as defined for this group for R¹ above; -CON(R¹¹)OR¹² where R¹¹ and R¹² independently represent H, C₁₋₄alkyl and C₂₋₄alkenyl;

a group of Formula II, -CONR¹³-CHR¹⁴-COOR¹⁷, where R¹³ is H or C₁₋₄alkyl, R¹⁷ is H or C₁₋₆alkyl, R¹⁴ is selected from the side chain of a lipophilic amino acid,

carbamoylC₁₋₄alkyl, N-(monoC₁₋₄alkyl)carbamoylC₁₋₄alkyl and N-(diC₁₋₄alkyl)carbamoylC₁₋₄alkyl, the group of Formula II having L or D configuration at the chiral alpha carbon in the corresponding free amino acid; a lactone of formula



C₁₋₄alkyl monosubstituted on carbon with =N-OH;

a group of Formula -X-R¹⁵ where X is selected from O, CO, CH₂, S, SO, SO₂ and R¹⁵ is selected from C₁₋₆alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R¹⁵ is optionally substituted as defined for the Ph group in R¹ = -C₁₋₃alkylene-Ph; p is 0-3 in which R³ values can be the same or different;

G is a linking moiety selected from the following groups written from left to right in Formula I:

-CO-NR¹⁶- where R¹⁶ is selected from H, C₁₋₄alkyl, C₁₋₄alkylene-Z, -CO-C₁₋₄alkylene-Z, -CO-C₁₋₆alkyl, -COZ, Z and Z is selected from -O-C₁₋₄alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R¹⁶ is optionally substituted as defined for the Ph group in R¹ = -C₁₋₃alkylene-Ph; -CH₂NR¹⁸- where R¹⁸ represents any value defined for R¹⁶; -CH₂S-; -CH₂O-; -CH₂CHR¹⁹- where R¹⁹ represents any value defined for R¹⁶; -CH=CR²⁰- where R²⁰ represents any value defined for R¹⁶; -CH₂NR²¹-T- where R²¹ represents any value defined for R¹⁶, T represents -(CH₂)_w- where w is 1-4 and T is optionally monosubstituted with R²² where R²² represents any value for R¹⁶ other than H; -CH₂NR²³-SO₂- where R²³ represents any value defined for R¹⁶; -CH₂NR²⁴-CO-T-CH₂NR²⁴-CO-T¹- where R²⁴ represents any value defined for R¹⁶, T¹ represents -(CH₂)_w- (CH₂)_w¹- where w w¹ is 0-4 and T¹ is optionally monosubstituted with R²⁹ where R²⁹ represents any value for R¹⁶ other than H; -CO-NR²⁵-T- where R²⁵ represents any value defined for R¹⁶, T represents -(CH₂)_w- where w is 1-4 and T is optionally monosubstituted with R²⁶ where R²⁶ represents any value for R¹⁶ other than H; -CH₂S-T- where T represents -(CH₂)_w- where w is 1-4 and T is

optionally monosubstituted with R^{27} where R^{27} represents any value for R^{16} other than H;
-CH₂O-T- where T represents -(CH₂)_w- where w is 1-4 and T is optionally monosubstituted
with R^{28} where R^{28} represents any value for R^{16} other than H;
A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring
containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N
& S;
or a -S-S- dimer thereof when $R^2=H$; or a N-oxide thereof;
or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate
thereof.